A citation-based method for searching scientific literature

Daniela Sia, Yang Jiao, Iris Martinez-Quetglas, Olga Kuchuk, Carlos Villacorta-Martin, Manuel Castro de Moura, Juan Putra, Genis Camprecios, Laia Bassaganyas, Nicholas Akers, Bojan Losic, Samuel Waxman, Swan N Thung, Vincenzo Mazzaferro, Manel Esteller, Scott L Friedman, Myron Schwartz, Augusto Villanueva, Josep M Llovet. Gastroenterology 2017
Times Cited: 317







List of co-cited articles
991 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
52

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
46

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel,[...]. Lancet Oncol 2018
927
42

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
33

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
32

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, Valeriy Breder, Julien Edeline, Yee Chao, Sadahisa Ogasawara,[...]. J Clin Oncol 2020
440
26

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim,[...]. Lancet Oncol 2019
578
26

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
Marina Ruiz de Galarreta, Erin Bresnahan, Pedro Molina-Sánchez, Katherine E Lindblad, Barbara Maier, Daniela Sia, Marc Puigvehi, Verónica Miguela, María Casanova-Acebes, Maxime Dhainaut,[...]. Cancer Discov 2019
162
26

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
26

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
26

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.
James J Harding, Subhiksha Nandakumar, Joshua Armenia, Danny N Khalil, Melanie Albano, Michele Ly, Jinru Shia, Jaclyn F Hechtman, Ritika Kundra, Imane El Dika,[...]. Clin Cancer Res 2019
176
25


Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony B El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, YenHsun Chen, Joong-Won Park,[...]. N Engl J Med 2018
830
24

Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.
Yutaka Kurebayashi, Hidenori Ojima, Hanako Tsujikawa, Naoto Kubota, Junki Maehara, Yuta Abe, Minoru Kitago, Masahiro Shinoda, Yuko Kitagawa, Michiie Sakamoto. Hepatology 2018
136
21


Hepatocellular Carcinoma.
Augusto Villanueva. N Engl J Med 2019
18

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Yujin Hoshida, Sebastian M B Nijman, Masahiro Kobayashi, Jennifer A Chan, Jean-Philippe Brunet, Derek Y Chiang, Augusto Villanueva, Philippa Newell, Kenji Ikeda, Masaji Hashimoto,[...]. Cancer Res 2009
655
17

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
Kornelius Schulze, Sandrine Imbeaud, Eric Letouzé, Ludmil B Alexandrov, Julien Calderaro, Sandra Rebouissou, Gabrielle Couchy, Clément Meiller, Jayendra Shinde, Frederic Soysouvanh,[...]. Nat Genet 2015
822
17

Molecular therapies and precision medicine for hepatocellular carcinoma.
Josep M Llovet, Robert Montal, Daniela Sia, Richard S Finn. Nat Rev Clin Oncol 2018
580
17

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang,[...]. Lancet Oncol 2009
17

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Jessica Zucman-Rossi, Augusto Villanueva, Jean-Charles Nault, Josep M Llovet. Gastroenterology 2015
582
16

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Sandrine Boyault, David S Rickman, Aurélien de Reyniès, Charles Balabaud, Sandra Rebouissou, Emmanuelle Jeannot, Aurélie Hérault, Jean Saric, Jacques Belghiti, Dominique Franco,[...]. Hepatology 2007
729
16

Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.
Chunhong Zheng, Liangtao Zheng, Jae-Kwang Yoo, Huahu Guo, Yuanyuan Zhang, Xinyi Guo, Boxi Kang, Ruozhen Hu, Julie Y Huang, Qiming Zhang,[...]. Cell 2017
705
15

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Julien Calderaro, Gabrielle Couchy, Sandrine Imbeaud, Giuliana Amaddeo, Eric Letouzé, Jean-Frédéric Blanc, Christophe Laurent, Yacine Hajji, Daniel Azoulay, Paulette Bioulac-Sage,[...]. J Hepatol 2017
240
15

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Austin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, Osama Rahma, Heiner Wedemeyer, Drew Pratt, Jeremy L Davis, Marybeth S Hughes, Theo Heller, Mei ElGindi,[...]. J Hepatol 2017
331
14

Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
Shu Shimada, Kaoru Mogushi, Yoshimitsu Akiyama, Takaki Furuyama, Shuichi Watanabe, Toshiro Ogura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban,[...]. EBioMedicine 2019
81
16

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski. Nature 2015
13

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Bruno Sangro, Ignacio Melero, Samir Wadhawan, Richard S Finn, Ghassan K Abou-Alfa, Ann-Lii Cheng, Thomas Yau, Junji Furuse, Joong-Won Park, Zachary Boyd,[...]. J Hepatol 2020
53
22

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Derek Y Chiang, Augusto Villanueva, Yujin Hoshida, Judit Peix, Philippa Newell, Beatriz Minguez, Amanda C LeBlanc, Diana J Donovan, Swan N Thung, Manel Solé,[...]. Cancer Res 2008
419
11

Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.
Roser Pinyol, Daniela Sia, Josep M Llovet. Clin Cancer Res 2019
58
18

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro, Carlos Gomez-Martin, Manuel de la Mata, Mercedes Iñarrairaegui, Elena Garralda, Pilar Barrera, Jose Ignacio Riezu-Boj, Esther Larrea, Carlos Alfaro, Pablo Sarobe,[...]. J Hepatol 2013
530
11

Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas.
Qi Zhang, Yu Lou, Jiaqi Yang, Junli Wang, Jie Feng, Yali Zhao, Lin Wang, Xing Huang, Qihan Fu, Mao Ye,[...]. Gut 2019
78
14

The Immune Landscape of Cancer.
Vésteinn Thorsson, David L Gibbs, Scott D Brown, Denise Wolf, Dante S Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, Galen F Gao, Christopher L Plaisier, James A Eddy,[...]. Immunity 2018
11

Robust enumeration of cell subsets from tissue expression profiles.
Aaron M Newman, Chih Long Liu, Michael R Green, Andrew J Gentles, Weiguo Feng, Yue Xu, Chuong D Hoang, Maximilian Diehn, Ash A Alizadeh. Nat Methods 2015
11

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, Andrew X Zhu, Max W Sung, Ari D Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko,[...]. J Clin Oncol 2020
180
11

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau, Yoon-Koo Kang, Tae-You Kim, Anthony B El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla,[...]. JAMA Oncol 2020
175
11

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere, Matthias Pinter, Marta Szydlowska, Revant Gupta, Mengjie Qiu, Aleksandra Deczkowska, Assaf Weiner,[...]. Nature 2021
90
12

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Jason J Luke, Riyue Bao, Randy F Sweis, Stefani Spranger, Thomas F Gajewski. Clin Cancer Res 2019
218
10

From NASH to HCC: current concepts and future challenges.
Quentin M Anstee, Helen L Reeves, Elena Kotsiliti, Olivier Govaere, Mathias Heikenwalder. Nat Rev Gastroenterol Hepatol 2019
331
10

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E Kadel, Hartmut Koeppen, Jillian L Astarita, Rafael Cubas,[...]. Nature 2018
10

The immunology of hepatocellular carcinoma.
Marc Ringelhan, Dominik Pfister, Tracy O'Connor, Eli Pikarsky, Mathias Heikenwalder. Nat Immunol 2018
326
10

Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, Catherine J Wu, Gad Getz, Nir Hacohen. Cell 2015
10

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D Baron, Tulio Eduardo Flesch Pfiffer,[...]. Lancet Oncol 2015
465
9

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
Jorge A Marrero, Laura M Kulik, Claude B Sirlin, Andrew X Zhu, Richard S Finn, Michael M Abecassis, Lewis R Roberts, Julie K Heimbach. Hepatology 2018
9

Hepatocellular carcinoma.
Josep M Llovet, Jessica Zucman-Rossi, Eli Pikarsky, Bruno Sangro, Myron Schwartz, Morris Sherman, Gregory Gores. Nat Rev Dis Primers 2016
9

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.
Celina Ang, Samuel J Klempner, Siraj M Ali, Russell Madison, Jeffrey S Ross, Eric A Severson, David Fabrizio, Aaron Goodman, Razelle Kurzrock, James Suh,[...]. Oncotarget 2019
49
18

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.
Yasushi Totoki, Kenji Tatsuno, Kyle R Covington, Hiroki Ueda, Chad J Creighton, Mamoru Kato, Shingo Tsuji, Lawrence A Donehower, Betty L Slagle, Hiromi Nakamura,[...]. Nat Genet 2014
430
9

Molecular and histological correlations in liver cancer.
Julien Calderaro, Marianne Ziol, Valérie Paradis, Jessica Zucman-Rossi. J Hepatol 2019
87
10

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Julien Calderaro, Benoît Rousseau, Giuliana Amaddeo, Marion Mercey, Cécile Charpy, Charlotte Costentin, Alain Luciani, Elie-Serge Zafrani, Alexis Laurent, Daniel Azoulay,[...]. Hepatology 2016
203
9

A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Ju Dong Yang, Pierre Hainaut, Gregory J Gores, Amina Amadou, Amelie Plymoth, Lewis R Roberts. Nat Rev Gastroenterol Hepatol 2019
871
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.